Pfizer Prices Bosulif With Eye Towards Leveling CML Playing Field
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer enters crowded competition for previously treated Ph+ chronic myelogenous leukemia with the newly approved bosutinib, but the firm hopes having a comparable price will level the playing field.